Primrose Bio, Inc., a company developing proprietary therapeutic manufacturing technologies has announced the launch of Prima RNApols™ ExTend, an RNA polymerase engineered to significantly improve manufacturing of long-template mRNA vaccines and therapeutics, including mRNA medicines based on self-amplifying mRNAs. This enzyme shows improved performance, resulting in superior mRNA quality at a lower cost.

Prima ExTend outperforms traditional T7 polymerase by generating higher-quality mRNA with lower dsRNA, eliminating a common challenge in mRNA manufacturing and enhancing downstream purification efficiency. Furthermore, Prima ExTend's transcription efficiency results in higher yield using lower amounts of key inputs, which can contribute to lower production costs.

"Prima ExTend is a much-needed innovation for the production of long-template mRNA therapeutics, that often struggle with integrity and quality issues that add risk to these programs. Our new enzyme is an important advancement for drug developers and researchers seeking high-integrity, high-yield mRNA," said Helge Zieler, CEO, Primrose Bio. 

"This innovation underscores our commitment to providing leading technologies that support the manufacturing of the next generation of mRNA vaccines and therapeutics," added Zieler.

Prima RNApols ExTend is available in an in vitro transcription kit for research use applications. GMP-grade Prima RNApols manufactured and released under ISO 13485:2016 certified quality systems are available for clinical and commercial mRNA manufacturing.